|
4.11 DÉP., DIAG. & PRONO. - OVAIRE
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
|
|
|
Yale test of immunotherapy drug for advanced lung cancer shows promise [Yale]
|
|
|
|
|
|
Lung cancer spreads to the brain in about one-quarter of patients with an advanced form of the disease. To date, radiation has been the only treatment option, but it comes with toxic side effects. Researchers at Yale Cancer Center (YCC) have found that use of the checkpoint inhibitor pembrolizumab in place of radiation can extend life with very few side effects in this patient population.
|
|
|
|
|
|
|
|
|
5.12.13 IMMUNOTHÉRAPIES - BIOMARQUEURS
|
|
|
|
5.2 PHARMA
|
|
|
|
5.2.1 PHARMA - PARTENARIATS
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
Selumetinib Approved by FDA to Treat Children with NF1 [NCI]
|
|
|
|
|
|
The approval was based on results from a clinical trial, designed and led by researchers in NCI’s Pediatric Oncology Branch (POB), which showed that the drug shrank neurofibromas in 70% of patients. For many children in the trial, treatment with selumetinib also had clinical benefit, improving their pain, function, and quality of life.
|
|
|
|
|
|
|
6.15 LUTTE CONTRE LES CANCERS - COVID-19
|
|
|
|